Compugen Shares Rocket Higher as Co. Announces Collaboration, License Deal with Bayer for Antibody-Based Cancer Immunotherapies

Compugen Ltd. (NASDAQ: CGEN ) announced today the signing of a collaboration and license agreement for the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy against two novel Compugen discovered immune checkpoint regulators. Under the terms of the agreement, Bayer HealthCare (Bayer) and Compugen will jointly pursue a preclinical research program. Subsequently,